+46 8 463 83 00
certifiedadviser@penser.se
About Nexstim Plc
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Sinch AB (publ): Sinch evaluates the conditions to carry out a directed new share issue GlobeNewswire May 24, 2021 NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE,.
Swedish
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES
Press Release
Stockholm 24 May 2021
Sinch completes a directed new share issue of 7,232,077 shares, raising approximately SEK 9.4 billion
Stockholm, Sweden – Sinch AB (publ) – XSTO: SINCH
Sinch AB (publ) (“Sinch” or the “Company”) has, in accordance with the Company’s press release earlier today and based on the authorization granted by the annual general meeting on 18 May 2021, resolved on a directed issue of 7,232,077 new shares at a subscription price of SEK 1,300 per share. Through the directed new share issue, the Company will raise approximately SEK 9.4 billion before issue costs. The subscription price has been deter
CoinShares Announces Record-Setting 2021 First Quarter Financial Results – Padovanews padovanews.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from padovanews.it Daily Mail and Mail on Sunday newspapers.
Nexstim Oyj: Nexstim Extends Agreement with Canadian Distributor and Receives Order for Three NBT Systems Nexstim or Company ) announces that it has extended its agreement with Canadian Health Solutions group, the Company s distributor in Canada, for an additional five years.
The agreement continues to focus on the distribution of Nexstim s NBT systems for the treatment of Major Depressive Disorder. In conjunction with this extension, the distributor has ordered three NBT systems and corresponding head trackers.
Mikko Karvinen, CEO of Nexstim, comments:
Considering the challenges presented by the global pandemic over the last 14 months, our relationship with Canadian Health Solutions has only strengthened. I am impressed by Dr. David Elias and his competent team and believe this initial order of three systems is only the beginning of providing Canadians with access to the most personalized TMS treatment for depression. There is great opportunity in this partnership.